On February 3, the U.S. Food and Drug Administration (FDA) approved Ibrance (palbociclib) to treat advanced metastatic breast cancer. Read more.
FDA approves Ibrance for postmenopausal women with metastatic breast cancer
*Online Bonus Content: This has not been peer reviewed. The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal.